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Abstract
Background: The secretory leukocyte protease inhibitor (SLPI) exerts wide ranging effects on inflammatory
pathways and is upregulated in EAE but the biological role of SLPI in EAE, an animal model of multiple sclerosis is
unknown
Methods: To investigate the pathophysiological effects of SLPI within EAE, we induced SLPI-neutralizing antibodies
in mice and rats to determine the clinical severity of the disease. In addition we studied the effects of SLPI on the
anti-inflammatory cytokine TGF-b.
Results: The induction of SLPI neutralizing antibodies resulted in a milder disease course in mouse and rat EAE.
SLPI neutralization was associated with increased serum levels of TGF-b and increased numbers of FoxP3+ CD4+ T
cells in lymph nodes. In vitro, the addition of SLPI significantly decreased the number of functional FoxP3+ CD25
hi
CD4+ regulatory T cells in cultures of naive human CD4+ T cells. Adding recombinant TGF-b to SLPI-treated
human T cell cultures neutralized SLPI’s inhibitory effect on regulatory T cell differentiation.
Conclusion: In EAE, SLPI exerts potent pro-inflammatory actions by modulation of T-cell activity and its
neutralization may be beneficial for the disease.
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Background
The secretory leukocyte protease inhibitor (SLPI) is an
11.7 kDa protein originally identified in bodily secretions
such as saliva, seminal fluid, and in the mucus of cervi-
cal, nasal and bronchial passages [1]. It was later found
in neutrophils, peritoneal macrophages, astrocytes and
neurons [2,3] as well as in activated regulatory T cells
[4], and was shown to be strongly upregulated in the
C N Sa sac o n s e q u e n c eo fi s c h e m i cs t r o k e[ 2 ] ,s p i n a l
cord injury [5] and experimental autoimmune encepha-
lomyelitis (EAE) [3]. SLPI is a potent inhibitor of leuko-
cyte serine proteases, including elastase and cathepsin G
from neutrophils, chymase and tryptase from mast cells,
and trypsin and chymotrypsin from pancreatic acinar
cells [6]. In addition, SLPI suppresses bacterial growth
[7], inhibits HIV-1 infection of macrophages [8] and
exerts anti-inflammatory functions in macrophages, neu-
trophils and B cells by inhibition of IBa degradation
[9,10]. Finally, SLPI diminishes inflammatory gene
expression and inflammatory cell accumulation after
hepatic and lung injuries [11], is neuroprotective in an
ischemic stroke model [2] and suppresses the expression
of matrix metalloproteinases by stimulated monocytes
[12].
Mice deficient in SLPI show impaired cutaneous
wound healing with increased inflammation. Addition-
ally, an increased TGF-b activity was found in these
mice, likely due to an increased proteolytic activation of
latent TGF-b in SLPI-deficient animals [13]. SLPI-
mediated suppression of TGF-b expression by human
endometrial cells [14] and SLPI’s inhibition on the
induction of regulatory T cell differentiation by elastase
[15] provide corroborating evidence that it has promi-
nent proinflammatory properties.
We investigated whether the effects of SLPI on the
immune system may have implications in diseases char-
acterized pathologically by inflammation as a result of
autoimmune mechanisms such as multiple sclerosis
(MS). Indeed SLPI is known to be markedly upregulated
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immune encephalomyelitis [3]. EAE can be induced by
immunization with myelin proteins which result in
auto-reactive CD4+ T cells to react with myelin and
cause concomitant clinical disease. The inflammatory
lesions in EAE strongly mimic the acute lesion in MS
[16,17]. Based on all these findings our studies aimed to
determine the role of SLPI in the pathogenesis of EAE
in SJL/J mice and DA rats and to study the impact of
SLPI on TGF-b activity.
Methods
Animals
Female dark agouti (DA) rats, 6-8-weeks old were pur-
chased from Harlan Laboratories (Indianapolis, IN), and
female SJL/J mice, 6-8-weeks old, were purchased from
the Jackson Laboratory (Bar Harbor, ME). Animals were
housed in the animal facility of Roosevelt Hospital (New
York, NY) and were 8-10-week old when used for
experiments. All procedures were conducted according
to protocols approved by the IACUC committee of Roo-
sevelt Hospital.
Induction and clinical evaluation of EAE
For active EAE induction, SJL/J mice were immunized
with 200 μL of a suspension containing 200 μgo fm u r -
ine PLP peptide (aa 139-151 (HSLGKWLGHPDKF),
Pepceuticals, Leicestershire, UK), and an equal volume
of CFA supplemented with 500 μg H37RA by subcuta-
neous injection to generate PLP-specific encephalito-
genic lymph node cells.
In order to induce the adoptive transfer EAE (at-
EAE) in SJL/J mice, lymph node cells were harvested
10 days after PLP-immunization and restimulated in
vitro f o rf o u rd a y sw i t h1 0μg/mL PLP-peptide. Naive
female SJL/J mice were injected intraperitoneally (ip)
with 1.5 × 10
7 preactivated PLP-specific LNC for at-
EAE induction.
To induce active EAE in DA rats, animals were
immunized subcutaneously at the base of the tail with
65 μg MOG1-125 emulsified in complete Freund’s
adjuvant (CFA) supplemented with 400 μgo fh e a t -
inactivated Mycobacterium tuberculosis (H37Ra)
(DIFCO Laboratories, Detroit, MI) in a total volume of
200 μL.
Animal weight and clinical score were recorded daily
(0 = healthy, 1 = limp tail, 2 = partial hind limb weak-
ness and/or ataxia, 3 = complete paralysis of at least one
hind limb, 4 = severe forelimb weakness, 5 = moribund
or dead). The mean cumulative score for a treatment
group was calculated as the sum of the daily scores of
all animals from day zero until the end of the experi-
ment divided by the number of animals in the respective
group.
Protein vaccination
SJL/J mice and DA rats were immunized i.p. with 100
μL of a solution containing 10 μg of SLPI (R&D Sys-
tems), respectively, mixed with 30 μL of the adjuvant
aluminum hydroxide (Aluhydrogel; Brenntag Biosector,
Frederikssund, Denmark). Vaccinations were performed
twice with an interval of 3 weeks as previously described
[18]. Control animals were injected with OVA peptide
(aa 323-339 ANASPEC (Fremont, CA)) and aluminum
hydroxide. After the second vaccination, animals rested
6 to 8 weeks before EAE was induced by adoptive trans-
fer of encephalitogenic lymph node cells (LNC) or
MOG-protein immunization, respectively.
Enzyme-linked immunosorbent assay (ELISA) for anti-SLPI
antibody detection
A direct ELISA assay was used to confirm SLPI-specific
IgG titers in sera from mice that had received the sec-
ond vaccination two weeks before. 96-well ELISA plates
(Nunc, Roskilde, Denmark) were coated overnight at 4°
C with recombinant SLPI protein (R&D Systems (Min-
neapolis, MN)) at concentrations of 100 ng/well. Plates
were washed with 0.1% PBS/Tween-20. Sera from SLPI
protein-vaccinated or OVA-vaccinated mice or rats were
then added in serial dilutions from 1:30 to 1:65610, and
the plates were incubated for 1 h at RT. After washing,
goat anti-mouse IgG conjugated to alkaline phosphatase
or respectively goat anti-rat IgG conjugated to alkaline
phosphatase (both from Sigma-Aldrich, St. Louis, MO)
were used as secondary antibodies with p-nitrophenyl-
phosphate (p-NPP; Sigma-Aldrich) as a substrate.
Confirmation of SLPI neutralization by serum SLPI
antibodies
IgG antibodies were purified from mice sera by utilizing
the MabTrap™ kit (Amersham Biosciences, Piscataway,
NJ) according to the manufacturer’s protocol. Antibody
titers to SLPI and OVA were confirmed by an ELISA
assay as described above.
U937 cells (ATCC; Manassas, Virginia) were cultured at
ad e n s i t yo f1×1 0
5 cells/200 μL RPMI medium in a 96-
well plate with LPS (100 ng/mL), 4 μg/mL SLPI and/or 40
μg/mL of purified total IgG from mice vaccinated with
either SLPI or OVA-peptide. After 2 h the cells were har-
vested, and RNA was isolated using the RNeasy Plus Mini
Kit (Qiagen). The IL-8 expression was quantified using IL-
8 specific Taqman probes (Hs99999034_m1, Applied Bio-
systems, Framingham, MA) and normalized to respective
18S rRNA quantities also determined by using Taqman
probes (Applied Biosystems).
SLPI administration
Recombinant SLPI (R&D Systems, Minneapolis, MN)
was administered ip to female SJL/J mice for the first
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SLPI group of mice was injected with SLPI (100 μL with
a SLPI concentration of 3.3 μg/mL in 0.9% saline), and
the control group of mice received 100 μL of 0.9% saline
instead. All mice received the injection ip three times a
day.
Quantification of TGF-b in serum samples
A direct ELISA assay was used to determine TGF-b
levels in serum samples isolated from mice on day 37
after EAE induction and from DA rats at day 14 after
EAE induction using the Mouse/Rat/Porcine/Canine
TGF-b1 immunoassay (R&D Systems). Total TGF-b
quantities were measured by incubating serum samples
with 1 M hydrogen chloride which activates latent TGF-
b. Activated TGF-b serum samples were analyzed with-
out the addition of HCl.
Isolation and cultivation of naive human CD4+ T cells
White blood cells were extracted from peripheral blood
using CPT BD Vacutainer tubes (BD Biosciences). Naïve
human CD4+ T cells were purified according to the
Naive CD4
+ T Cell Isolation Kit II instructions (Miltenyi
Biotec, Bergisch Gladbach, Germany).
100,000 Naïve human CD4+ T cells per 0.2 mL of
RPMI were cultivated in U bottom-shaped 96-well
plates. Cells were stimulated with aCD3- and aCD28-
microbeads (Dynabeads
® Human T-Activator CD3/
CD28, Invitrogen) in serum-free “Stem Line T cell
expansion medium” (Sigma Aldrich).
Determination of TGF-b expression by U937 cells
U937 cells (ATCC; Manassas, Virginia) were cultured at
a density of 1 × 10
5 cells/200 μL RPMI medium in a 96-
well plate with or without 500 ng/ml SLPI (R&D Sys-
tems). After 16 h the cells were harvested, and RNA
was isolated using the RNeasy Plus Mini Kit (Qiagen).
The TGF-b expression was quantified using TGF-b spe-
cific Taqman probes (Hs00998133_m1, Applied Biosys-
tems) and normalized to respective 18S rRNA quantities
also determined by using Taqman probes (Applied
Biosystems).
Flow cytometry
Flow cytometric analyses were carried out with a FAC-
SARIA flow cytometer (BD Biosciences). After staining
the cell surfaces, the cells were washed, fixed and per-
meabilized with the BD Cytofix/Cytoperm-Kit (BD Bios-
ciences) and stained for intracellular molecules. The
following antibodies were used for murine cells: Pacific
Blue anti-CD4 (RM4-5) (BD Bioscience), PE anti IL-17A
(clone eBio17B7) and APC anti-IFN-g (clone XMG1.2)
(both from eBioscience, San Diego, CA) and with Alexa-
Fluor647 anti-FoxP3 ((clone 259D) BioLegend, San
Diego, CA). Human cells were stained with eFluor450
anti-CD4 (clone OKT4), PE anti-IFN-g (clone 4S.B3),
FITC anti-IL-17 (clone eBio64DEC17), PE anti CD25
(clone BC96) (all four from eBioscience) as well as with
AlexaFluor647 anti-FoxP3 (clone 259D) or Alexa-
Fluor647 isotype antibody (AlexaFluor 647 mouse IgG1,
, BioLegend).
To detect the proliferation of stimulated naïve human
CD4+ T cells, cells were stained with 2.5 μMC F S E
using the CellTrace™ CFSE Cell Proliferation Kit (Invi-
trogen, Carlsbad, CA) according to the manufacturer’s
instructions. The number of divisions was determined
by counting the number of peaks. For the detection of
intracellular IL-17 and IFN-g in CFSE stained cells,
Alexa Fluor700 anti-IL-17a (clone N49-653, BD Bios-
ciences) and PE-Cy7 anti-IFN-g (clone 4S.B3, BioLe-
gend) antibodies were used. Additionally, antibodies of
the same isotype as the FoxP3 antibody (AlexaFluor 647
mouse IgG1, , BioLegend) were used for staining.
Statistical analyses
Statistical analyses were performed using SigmaStat 3.0
(IBM, Somers, NY). Comparisons of groups of normal-
distributed data were done by Student’s t-test or an
ANOVA analysis. For non-normally distributed data
from the EAE experiments the Mann-Whitney Rank
Sum test was used for comparison. Error bars represent
standard deviations unless otherwise indicated.
Results
Vaccination of SJL/J mice with SLPI protein induces SLPI-
specific neutralizing antibodies
Previously, we reported that SLPI is strongly induced
within the spinal cord during the disease course of the
MOG-induced EAE of DA rats [3]. To further address
this observation, we induced neutralizing SLPI antibo-
dies in vivo in order to neutralize SLPI and to assess its
function during CNS inflammation. In particular, we
immunized female SJL/J mice with human recombinant
SLPI protein and control mice with ovalbumin peptide
(OVA). Vaccinations were performed twice with an
interval of three weeks and resulted in high and repro-
ducible antibody titers for SLPI (Figure 1A).
To confirm that the induced SLPI-specific antibodies
were able to neutralize SLPI’s activity, we determined if
they were able to prevent the SLPI-mediated inhibition
of the LPS-induced production of IL-8 by the human
monocytic cell line U937 [9]. We found that, serum IgG
from SLPI-vaccinated mice neutralized SLPI’s inhibitory
effect on the LPS-induced IL-8 expression. In contrast,
serum IgG isolated from control OVA-vaccinated mice
had no impact on the inhibition of the LPS-mediated
induction of IL-8 by SLPI (Figure 1B). These data con-
firmed that protein vaccination with recombinant SLPI
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neutralize biological effects of soluble SLPI in vitro.
SLPI blockade is protective in passive EAE of female SJL/J
mice and in active EAE of DA rats
To investigate the role of SLPI in vivo, we examined the
consequences of its neutralization in the passive EAE of
SJL/J mice. For the induction of adoptive transfer EAE,
donor SJL/J mice were immunized with PLP peptide.
Their lymph node cells (LNC) were harvested 10 days
later and restimulated in vitro f o rf o u rd a y sw i t hP L P .
1.5 × 10
7 LNC were subsequently transferred into mice
which had been immunized with OVA- or SLPI-protein
two months beforehand.
Mice vaccinated with SLPI protein developed a signifi-
cantly less severe EAE disease course than the OVA-
immunized animals (Figure 2A, Table 1) correlating
with a significantly delayed disease onset in SLPI immu-
n i z e dm i c ec o m p a r e dt oO V A - i m m u n i z e dm i c e .T h i s
Figure 1 SLPI protein vaccination induces neutralizing SLPI-
specific antibodies. A: Mouse sera collected 14 days after the
second vaccination with SLPI- or OVA-protein were analyzed by
ELISA for the presence of SLPI-specific antibodies, as described in
Materials and Methods. IgG titers representing the average of
samples from six different mice were compared. B: U937 monocytic
cells were incubated with 4 μg/mL SLPI with either 40 μg/mL IgG
antibodies purified from sera of SLPI-vaccinated mice or from OVA-
vaccinated mice and stimulated for 2 h with 100 ng/mL LPS. The IL-
8 expression was quantified by Real Time-PCR. Results are shown as
mean ± standard deviation of three samples. The differences
between LPS-stimulated cells and control cells, between SLPI and
LPS-treated cells and just LPS treated cells, between LPS- and SLPI-
treated cells and cells treated with SLPI, LPS and SLPI-IgG and
between SLPI, LPS and SLPI-IgG and SLPI, LPS and OVA-IgG treated
U937 cells were statistically significant at p < 0.05 (One-Way ANOVA
and Holm-Sidak test)
Figure 2 SLPI protein vaccination protects against adoptive
transfer EAE in mice and active EAE in rats. A: SJL/J mice were
vaccinated twice with SLPI or OVA and aluminum hydroxide. Six
weeks after the last vaccination, EAE was induced by i.p. injection of
encephalitogenic PLP specific LNC. Data are representative of two
independent experiments and are shown as mean ± S.E. of the
mean. The differences between the SLPI and the control group
were statistically significant throughout the whole experiment after
day 18 (Mann- Whitney rank sum test, p < 0.05). B: DA rats were
vaccinated twice with SLPI- or OVA-protein and aluminum
hydroxide. Six weeks after the last vaccination, EAE was induced by
immunization with recombinant MOG protein. Data are
representative of two experiments and are shown as mean ± S.E. of
the mean. The differences between the SLPI and the control group
were statistically significant on days 15 and 16 after disease
induction as well as after day 25 (Mann-Whitney rank sum test, *, p
< 0.05)
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induction of SLPI-specific antibodies had an ameliora-
tive effect on the clinical course of EAE.
We next studied the impact of SLPI neutralization on
the active MOG-induced EAE of DA rats, because we
previously showed that SLPI is substantially upregulated
in the spinal cord in this model [3]. Rats were vacci-
nated in the same manner as the SJL mice with SLPI-
or OVA-protein. Protein vaccination of rats also
induced specific antibody titers for SLPI and OVA,
respectively, as measured by ELISA (Additional file 1:
Figure S1). While the onset of clinical disease after
immunization with MOG 1-125 was not significantly
delayed in SLPI-vaccinated rats, they developed a signifi-
cantly milder disease course than mice vaccinated with
OVA protein (Figure 2B, Table 1). Thus, the induction
of SLPI-neutralizing antibodies decreases EAE disease
severity in two species, irrespective of the autoantigen
used for disease induction.
In order to corroborate SLPI’s pathogenic role in EAE,
we administered recombinant SLPI to SJL/J mice which
have been immunized with PLP-peptide for active EAE
induction. The SLPI group was injected intraperitoneally
three times a day for sixteen days with SLPI (100 μL
with a SLPI concentration of 3.3 μg/mL in 0.9% saline),
control mice received 100 μL of 0.9% saline instead.
SLPI treated mice developed disease signs earlier than
t h ec o n t r o lm i c ea n dh a dam o r es e v e r ed i s e a s ec o u r s e
(Additional file 2: Figure S2A, Table 1). After stopping
the administration of SLPI, the SLPI-treated animals
became similar to the control mice. This might be
explained by the limited half-life of SLPI in vivo [19].
The observed increase of disease symptoms of SLPI-
treated mice after day 16 could also have been caused
by the induction of SLPI antibodies, because we found
high serum SLPI antibody titers in SLPI-immunized
mice at day 30 after EAE induction (Additional file 2:
Figure 2B).
SLPI has an inhibitory effect on TGF-b in vivo and in vitro
SLPI is known to be an inhibitor of the anti-inflamma-
tory molecule TGF-b by two different mechanisms: sup-
pressing the expression of TGF-b [14] and interfering
with TGF-b’s proteolytic activation [13]. It was also
described to interfere with the differentiation of TGF-b
producing regulatory T cells induced by neutrophilic
elastase [15].
Firstly, we incubated U937 cells U937 for 16 h with
500 ng/mL of recombinant SLPI, a SLPI concentration
previously determined to have the greatest impact on
the differentiation of neural stem cells [3]. Interestingly,
SLPI strongly suppressed the expression of TGF-b quan-
tified by RealTime-PCR (Figure 3A).
Next, we quantified TGF-b in sera obtained from
S L P I -a n dO V A - i m m u n i z e dm i c ea tt h ee n do ft h e
experiment shown in Figure 2A and in serum samples
isolated from rats at day 14 after EAE induction. Total
TGF-b serum levels were significantly higher in SLPI-
immunized than in OVA-immunized mice (Figure 3B).
SLPI-immunized rats had significantly increased total
and activated TGF-b level compared to OVA-immu-
nized rats on day 14 after EAE induction (Figure 3C)
suggesting that SLPI inhibits TGF-b production in vivo.
SLPI inhibits differentiation of regulatory T cells
As TGF-b favors the generation of regulatory T cells, we
investigated if SLPI interferes directly with the differen-
tiation of regulatory T cells. Naïve human CD4+ T cells
isolated from human blood were incubated for six days
in serum-free medium in the presence or absence of
500 ng/mL SLPI protein. We detected fewer FoxP3+
CD25
hi CD4+ regulatory T cells in those T cell cultures
Table 1 Clinical parameters of EAE experiments in SJL/J mice and DA rats (*, p < 0
Incidence
Mortality
Disease onset [d] ±
StdDev
Cumulative score ±
StdDev
Mean maximal score ±
StdDev
SLPI immunization in passive EAE of SJL/J
mice
SLPI-immunized mice 10/
10
0/
10
23.0 ± 4.6 * 8.9 ± 4.6 * 2 ± 0.5
OVA-immunized mice 7/7 0/7 17 ± 2.8 21.4 ± 7.5 2.6 ± 0.7
SLPI immunization in active EAE of DA rats
SLPI-immunized rats 7/8 1/8 20.9 ± 10.8 21.2 ± 19.3 2.8 ± 2.0 *
OVA-immunized rats 8/8 3/8 13.8 ± 1.8 30.7 ± 9.3 4.5 ± 0.8
SLPI administration in active EAE of SJL/J
mice
SLPI-treated mice 6/7 1/7 11.1 ± 2.4 * 29.7 ± 15.3 3.1 ± 1.5
saline-treated mice 5/5 0/5 15.2 ± 4.4 19.8 ± 5.7 2.8 ± 0.4
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4B) indicating that the SLPI decreases the generation of
regulatory T cells. By contrast there were no differences
in the number of Th1 and Th17 cells between SLPI
treated- and control treated T cell cultures; no Th17
cells were detectable and less than 1% of the CD4+ T
cells were Th1 cells (Additional file 3: Figure S3).
We next determined whether the SLPI-mediated
decrease of CD4+ FoxP3+ T cells correlated with a
reduced regulatory activity of SLPI-treated naïve human
CD4+ T cells. Human naïve CD4+ T cells were stimu-
lated with anti CD3- and CD28-antibody-coated beads
with or without 500 ng/mL of SLPI as previously
described. After four days, cells were further cultured at
various ratios with fresh naïve CD4+ T cells isolated
from the same donor and stained with CFSE. FACS
analyses revealed that CSFE labeled CD4+ T cells cocul-
tured with SLPI treated T cells for four days showed sig-
n i f i c a n t l ym o r ep r o l i f e r a t i on than cells cocultured with
control treated T cells (Figures 4C and 4D) confirming
that SLPI interferes with the regulatory activity of T cell
cultures.
To validate that the observed effect on regulatory
activity is mediated by suppression of TGF- b,n a ï v e
SLPI-treated CD4+ T cell cultures were supplemented
with active human TGF-b (R&D Systems) and incu-
bated for three days. The addition of only 500 pg/mL
of TGF- b neutralized the effect of SLPI on the differ-
entiation on FoxP3+ regulatory T cells completely (Fig-
ure 4E) corroborating that SLPI is interfering with the
differentiation of regulato r yTc e l l sb yi n h i b i t i n gt h e
activation of TGF- b.
Figure 3 SLPI has an inhibitory effect on TGF-b. A: 100,000 U937 cells were incubated for 16 h in 0.2 mL RPMI medium with or without SLPI.
TGF-b expression was quantified by RealTime-PCR (**, p < 0.01 (Student’s t-test)) B: Blood was drawn from SLPI- and OVA-immunized mice at
the end of the experiment shown in Figure 2A. Total TGF-b was quantified after activation of latent TGF-b in the samples by hydrogen chloride
treatment. Differences between samples from SLPI-immunized and OVA-mice immunized were tested for their statistical significance using a
Student’s t-test. (*, p < 0.05) C: Blood was drawn from SLPI- and OVA-immunized rats at day 14 after EAE induction. Total TGF-b has been
quantified after activation of latent TGF-b in the samples by hydrogen chloride treatment. Activated TGF-b levels were determined by skipping
the activation step. Differences of total and activated TGF-b levels between samples isolated from SLPI-immunized and OVA-immunized rats
were tested for their statistical significance using a Student’s t-test. (*, p < 0.05)
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regulatory T cell differentiation. In particular, we exam-
ined if the neutralization of SLPI decreases the number
of these anti-inflammatory T cells. SLPI- and OVA-
immunized SJL/J mice were sacrificed before EAE onset
on day 12 after induction of adoptive transfer EAE and
cells were extracted from inguinal lymph nodes. Analo-
gous to the in vitro experiment, mice immunized with
SLPI-protein showed increased numbers of CD4+ FoxP3
+ regulatory T cells in lymph nodes compared to OVA-
immunized animals (Figure 5) providing further evi-
dence that the neutralization of SLPI increases the gen-
eration of regulatory T cells.
On the other hand, SLPI-immunization did not cause
any difference in the number of Th1 and Th17 cells in
lymph nodes at the end of the EAE experiment pre-
sented in Figure 2A. SLPI-and OVA-immunized mice
were sacrificed on day 37 after induction of adoptive
transfer EAE, their lymph nodes extracted and
stimulated in vitro with PMA, Ionomycin and Brefeldin
A for intracellular cytokine staining. No differences in
the number of Th1 and Th17 cells were found (Addi-
tional file 4: Figure S4).
Discussion
MS is a disease of unknown etiology in which there is
substantial clinical and pathological evidence of auto-
immune dysfunction [16,17]. The disease activity in MS
at any time point likely reflects the state of equilibrium
between pro-inflammatory and anti-inflammatory sig-
nals. Systemic immune activation, the integrity of the
blood-brain barrier, and inflammatory events within the
brain and spinal cord all contribute to demyelination
and axonal damage [20]. The role of proteases in MS
pathogenesis is of interest because they have crucial reg-
ulatory roles in inflammatory processes through a num-
ber of different mechanisms. These include modification
and induction of chemokines and cytokines, activation
Figure 4 SLPI reduces generation of regulatory T cells in vitro. A: Human naïve CD4+ T cells were stimulated with anti-CD3- and anti-CD28-
coated beads in serum-free medium in the absence or presence of 500 ng/mL SLPI. After six days, cells were analyzed by flow cytometry for
CD4 (DAPI channel (not shown)), CD25 (PE channel) and FoxP3 (APC channel). Left side: Dot blot representing staining with an antibody of the
same isotype as the FoxP3 antibody (AlexaFluor 647 mouse IgG1, k, BioLegend), middle: representative dot blot of control treated naïve human
CD4+ T cell cultures, right side: representative dot blot of T cell cultures incubated with 500 ng/mL SLPI. B: Column chart shows the average
concentration of FoxP3+ CD25
hi CD4+ T cells in CD4+ T cell cultures. p = 0.011 comparing FoxP3+ CD25
hi CD4+ T cells incubated with and
without 500 ng/mL SLPI. C: Human naïve CD4+ T cells were stimulated with anti-CD3- and anti-CD28-coated beads in RPMI medium in the
absence or presence of 500 ng/mL SLPI. After four days, the cells were cocultured at a ratio of 1:5 with naïve CFSE labeled CD4+ T cells from
the same donor. The CFSE profiles of the labeled cells were determined after 4 days. The number of divisions was determined by counting the
number of peaks. Representative histogram of CSFE labeled T cells. D: Bars represent the proportion of CFSE labeled CD4+ T cells which
proliferated and the total number of CFSE labeled cells. For every number of divisions, the differences between cell cultures containing SLPI-
treated T cells and control treated T cells were tested for their statistical significance using a Suet’ t-test (*, p < 0.05; **, p < 0.01). E: Human
naïve CD4+ T cells were stimulated with anti-CD3- and anti-CD28-coated beads in RPMI medium in the absence or presence of 500 ng/mL SLPI
and various concentrations of TGF-a. After four days, the cells were analyzed by flow cytometry for CD4 (DAPI channel), CD25 (PE channel) and
FoxP3 (APC channel). The columns represent the average density of FoxP3+ CD4+ T cells in the in vitro cultures. *: p < 0.05 comparing FoxP3+
CD4 T cells incubated with and without SLPI
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immunized SJL/J were sacrificed 12 days after passive EAE induction. LNC were extracted and analyzed by flow cytometry for CD4 (DAPI
channel) and FoxP3 (APC channel). Result from a representative OVA-immunized mouse is shown in the upper diagram and from a SLPI-
immunized mouse in the lower diagram. B: Column chart represents the average ratio of FoxP3+ CD4+ and total number of CD4+ T cells in
inguinal lymph nodes of SLPI- and OVA-immunized mice on day 12 after passive EAE induction (***, p < 0.001, Student’s t-test)
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activation of TLR4 and matrix metalloproteinases
(MMPs) (reviewed in [21,22]). In CNS inflammation in
particular, MMPs may contribute to inflammatory
damage through disruption of the blood brain barrier
[23] and by cleaving myelin proteins [24]. Further inves-
tigation and understanding of the role of proteases in
MS is therefore important to enable development of
therapeutic strategies that modulate CNS inflammation
[25].
To further elucidate the role of proteases in MS we
studied the effects of the protease inhibitor SLPI in
EAE, the accepted disease model of MS. SLPI is of inter-
est because in addition to its competitive inhibition of
several proteases [6], it is upregulated in EAE [3] and
has both anti-and pro-inflammatory on the immune sys-
tem. SLPI exerts anti-inflammatory effects on macro-
phages, neutrophils [9] and B cells [10]. It also regulates
inflammatory responses by reducing inflammatory gene
expression and diminishing inflammatory cell accumula-
tion following tissue injury [11,26]. However, mice defi-
cient in SLPI have increased TGF-b activity suggesting a
pro-inflammatory SLPI function [13]. Moreover, SLPI
suppresses TGF-b [14] and reduces the differentiation of
human regulatory T cells induced by elastase [15].
We examined the role of SLPI in two different EAE
models, namely, the PLP-induced EAE of SJL/J mice
and the MOG-induced EAE in DA rats. While the for-
mer is a versatile model of relapsing T-cell mediated
CNS inflammation [27], the latter, with features such as
relapses, chronicity, extensive demyelination and contri-
bution of both cellular and antibody-mediated effects,
more closely resembles MS [28].
In order to study the role of SLPI within these animal
models, we induced SLPI-specific antibodies by immu-
nizing animals with recombinant SLPI protein together
with the adjuvant aluminum hydroxide. Control animals
were vaccinated with ovalbumin peptide and adjuvant.
We cannot completely exclude that SLPI protein differs
in its immunogenicity from ovalbumin peptide resulting
in an unspecific modulation of the animals’ immune sys-
tem, but we did not find a difference in the number of
Th1 or Th17 in the lymph nodes of SLPI- and OVA-
immunized mice during EAE. Moreover, we waited six
to eight weeks after the second SLPI vaccination before
inducing EAE in order to reduce the nonspecific effects
of the immunization procedure on EAE pathogenesis.
We tested the antibodies’ capacity to neutralize SLPI in
vitro. Only IgG isolated from SLPI-immunized but not
from control-vaccinated animals prevented SLPI’si n h i -
bition of LPS-induced IL-8 induction [9]. This data
strongly suggests that we were able to induce SLPI-spe-
cific antibodies which block SLPI mediated effects and
this effect was not a function of a generalized immune
activation.
Despite the well-established influence of SLPI on
immune reactions, this is the first report showing that
SLPI influences inflammatory CNS diseases. In our
experiments, mice which received recombinant SLPI for
the first sixteen days after EAE induction developed a
more severe disease course than control injected mice.
After day 20 the two treatment groups had a similar dis-
ease severity, probably due to the limited half-life of
SLPI [19] and to the induction of SLPI-specific antibo-
dies in vivo.
On the other hand, the neutralization of SLPI by gener-
ating functional anti-SLPI antibodies induced by SLPI
protein immunization of SJL/J mice and DA rats resulted
in decreased EAE disease severity in both MS models.
We speculate accordingly that the protection mediated
by SLPI antibodies is a general phenomenon which is
independent of the myelin antigen used for EAE induc-
tion as well as of the procedure to induce EAE.
The milder disease course in SLPI-immunized rats
and mice was paralleled by increased sera levels of TGF-
b compared to OVA-immunized animals. These data
suggest that in EAE, the pro-inflammatory functions of
SLPI probably associated with down regulation of TGF-
b described above have a greater impact than SLPI’s
anti-inflammatory effects. TGF-b controls proliferation
and differentiation of a number of cell types involved in
acquired and innate immunity (reviewed in [29]). In par-
ticular reference to MS, TGF-b upregulates CD25+
Foxp3+ regulatory T-cells and systemic administration
of TGF-b is associated with amelioration of inflamma-
tory activity in EAE [30].
In our studies the mechanism of amelioration of dis-
ease severity in EAE associated with anti-SLPI antibo-
dies is not established, but we hypothesized that it is in
part due to the increased TGF-b serum levels which
may enhance the generation of anti-inflammatory CD25
+, Foxp3+ regulatory T-cells. Indeed in our EAE disease
mouse model we found an increased number of CD25
hi,
Foxp3+ regulatory T-cells in lymph nodes compared the
numbers seen in control animals. Furthermore, SLPI
suppresses the expression of TGF-b in monocytic U937
cells, and mitogenically stimulated naïve human CD4+
T cell cultures derived from healthy donors contained
significantly fewer regulatory T cells when incubated
with SLPI protein. Additionally, SLPI treated T cell cul-
tures showed a decreased ability to regulate the prolif-
eration of CFSE labeled CD4+ T cells compared to
results with cultures not containing SLPI. Supplementa-
tion of very small amounts of active TGF-b neutralized
SLPI’s inhibitory impact on the generation of regulatory
T cells completely.
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sion of TGF-b-remains to be elucidated. SLPI’s ability to
inhibit the activation of NFB may contribute to TGF-b,
as the activation of NFB induces TGF-b [31]. Imma-
ture dendritic cells exposed to elastase secrete higher
amounts of TGF-b [15]. Hence, the inhibition of elastase
activity by SLPI [7] may also contribute to the observed
suppression of TGF-b by SLPI in our studies.
These experiments support our hypothesis that the
neutralization of SLPI is protective in adoptive transfer
and active EAE probably because of an increase of TGF-
b serum level promoting the differentiation of regulatory
T cells. In previous work we had shown increased spinal
expression of SLPI during MOG-induced EAE of DA
rats and had speculated that SLPI was protective in the
disease model because of its anti-inflammatory functions
[3]. Our current experiments, however, suggest that the
neutralization of SLPI effects in EAE leads to elevated
TGF-b serum levels and is disease protective. Thus, the
increased expression of SLPI in EAE in our previous
work is likely a deleterious factor counteracting the
TGF-b-mediated regulatory immune responses in the
CNS.
Conclusions
The influence of SLPI on CNS autoimmunity was not
addressed before. Despite SLPI’s manifold anti-inflam-
matory properties, the severity of both, rat murine EAE,
was reduced by the induction of neutralizing SLPI anti-
bodies. We provide evidence that SLPI exerts pro-
inflammatory functions by interference with the produc-
tion and/or activation of the anti-inflammatory molecule
TGF-b. Further studies are warranted to define SLPI’s
role within CNS autoimmunity.
Additional material
Additional file 1: Figure 1. SLPI immunization of DA rats induces SLPI
specific antibodies. Rat sera collected 14 days after the second
vaccination with SLPI- or OVA-protein were analyzed by ELISA for the
presence of SLPI-specific antibodies, as described in Materials and
Methods. Results represent the optical density at 405 nm (OD405). IgG
titers represent the average (Av) titers of six different rats.
Additional file 2: Figure 2. SLPI administration increases severity of
active PLP-induced EAE of SJL/J mice. A: Female SJL/J mice were
immunized with PLP-peptide. Between 0 and 16 days, SLPI mice were
injected three times a day with recombinant SLPI (100 μL of 3.3 μg/mL
in 0.9% saline); control mice were injected with 0.9% saline instead. Data
is shown as mean ± S.E. of the mean. The differences between the SLPI
and the control group were statistically significant on day 19 after
disease induction (Mann-Whitney rank sum test, p < 0.05). B: Mouse sera
collected 30 days after EAE induction were analyzed by ELISA for the
presence of SLPI-specific antibodies, as described in Materials and
Methods. IgG titers representing the average of samples from five
different mice were compared
Additional file 3: Figure 3. SLPI treatment of human naïve CD4+ T cell
culture does not influence differentiation of Th1 and Th17 cells. A:
Human naïve CD4+ T cells were stimulated with anti-CD3- and anti-
CD28-coated beads in RPMI medium in the absence or presence of 500
ng/mL SLPI. After four days, the cells were activated with PMA,
Ionomycin and Brefeldin A for 4 h and analyzed by flow cytometry for
CD4 (DAPI channel), IFN-g (Pe-Cy7 channel) and IL-17 (FITC channel). Left
side: Representative dot blot of control treated naïve human CD4+ T cell
cultures, right side: representative dot blot of T cell cultures incubated
with 500 ng/mL SLPI. B: The column chart shows the average
concentration of IFNg + CD4+ T cells in the CD4+ T cell cultures. p =
0.11 comparing numbers of IFNg + CD4+ T cells incubated with 500 ng/
ml SLPI and without SLPI. A respective diagram showing the average
number of Th17 cells is not shown due to the lack of these cells in our T
cell cultures.
Additional file 4: Figure 4. SLPI immunization does not modulate Th1
and Th17 immune responses. OVA- or SLPI-immunized SJL/J were
sacrificed 37 days after passive EAE induction. LNC were extracted, in
vitro restimulated with PMA, Ionomycin and Brefeldin A and analyzed by
flow cytometry for CD4 (DAPI channel), IFN-g (APC channel) and IL-17
(PE channel). Mice immunized with SLPI protein showed no significant
difference to OVA-immunized mice with regards to the number of Th1
and Th17 cells.
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